Research Highlight |
Featured
-
-
Research Highlight |
Preventing sudden cardiac death early after myocardial infarction—ICDs are not the solution
- Alexandra King
-
-
-
-
-
Research Highlight |
Long-term cardiac mortality increased in men with PON-1 gene mutations
- Alexandra King
-
-
News & Views |
The AMADEUS study in perspective
The Carillon system is a percutaneously delivered, coronary-sinus-based mitral annuloplasty device. A safety and feasibility trial now demonstrates low rates of major adverse events, with improvements in quality of life. Though promising, this report raises important questions related to relative efficacy and durability compared with other relevant therapies, and related to current clinical indications.
- Jason H. Rogers
- & Steven F. Bolling
-
News & Views |
A promising new anticoagulant for stroke prevention
Stroke is the leading cause of morbidity and mortality in patients with atrial fibrillation. Whereas warfarin reduces the risk of stroke, its interactions with other drugs and food, individual differences in its efficacy and the need for frequent monitoring make its use inconvenient. Dabigatran etexilate might represent a step forward in the care of patients with atrial fibrillation.
- Sarah A. Spinler
-
News & Views |
Dronedarone and amiodarone—the safety versus efficacy debate
Amiodarone effectively maintains sinus rhythm in patients with atrial fibrillation, and although dronedarone is less effective it has a better safety profile. The choice of antiarrhythmic drug (or nonpharmacological strategy) depends on the ultimate goal of therapy, which should be considered in the context of the patient's clinical presentation and the treatment tailored to the individual.
- Eric N. Prystowsky
-
News & Views |
Indications for ICD–CRT in mildly symptomatic heart failure
Clinical trial data, including those from MADIT-CRT, support the use of cardiac resynchronization therapy in patients with asymptomatic and mildly symptomatic heart failure and ventricular dyssynchrony. However, important questions remain about which of these patients benefit most from this therapy.
- Johannes Holzmeister
- & William T. Abraham
Targeting collagen metabolism in preserved systolic function HF
Is tecarfarin a better anticoagulant than warfarin?